Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Prediabetes Market

Prediabetes Market Size

  • Report ID: GMI8874
  • Published Date: Apr 2024
  • Report Format: PDF

Prediabetes Market Size

Prediabetes Market size was valued at around USD 198.4 million in 2023 and is estimated to reach over USD 360.6 million by 2032 with a CAGR of 6.9%. Prediabetes is a condition characterized by blood sugar levels that are higher than normal but not yet high enough to be classified as type 2 diabetes. It is considered an intermediate stage between normal glucose levels and diabetes. One of the primary catalysts for the market is the rising prevalence of prediabetes worldwide.


Factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and aging populations contribute to the growing prevalence of prediabetes. For instance, in 2021, the Centers for Disease Control and Prevention (CDC) reported that there was a total of 97.6 million adults aged 18 years or older with prediabetes, comprising 38.0% of the adult population in the U.S. Among adults aged 65 years or older, 27.2 million individuals, accounting for 48.8% of this age group, were identified as having prediabetes. Thus, as more people are diagnosed with prediabetes, there is an increasing demand for preventive measures and interventions to manage and potentially reverse this condition.

Pharmaceutical companies are investing in research and development to innovate antidiabetics drug formulations for the management of prediabetes. These innovations include advance pharmaceutical drug delivery which is estimated to reach USD 3.2 trillion by 2032, such as novel drug delivery systems, combination therapies, and medications with improved efficacy and safety profiles. By developing more effective pharmacological interventions for prediabetes, companies aim to address the unmet medical needs of individuals at risk of developing type 2 diabetes and enhance the options available for healthcare providers.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prediabetes industry size recorded USD 198.4 million in 2023 and will grow at a 6.9% CAGR between 2024 and 2032 owing to rise in obesity rates and sedentary lifestyles, emphasis on preventive healthcare measures and investments in screening programs.

The biguanides segment in the prediabetes industry will register USD 254.6 million by 2032, attributed to the effectiveness and widespread use of biguanides, such as metformin, as a first-line treatment for prediabetes.

North America prediabetes industry captured 40.7% revenue share in 2023, driven by high prevalence of prediabetes in the region, rising obesity rates, and sedentary lifestyles.

Prominent prediabetes firms are Abbott Laboratories, AstraZeneca PLC, CH Boehringer Sohn AG & Co KG, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.

Prediabetes Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 217
  • Countries covered: 22
  • Pages: 167
 Download Free Sample